Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.

The research and development process in the field of rare diseases is characterised by many well-known difficulties, and a large percentage of orphan medicinal products do not reach the marketing approval.This work aims at identifying orphan medicinal products that failed the developmental process and investigating reasons for and possible factors influencing failures. Drugs designated in Europe under Regulation (European Commission) 141/2000 in the period 2000-2012 were investigated in terms of the following failures: (1) marketing authorisation failures (refused or withdrawn) and (2) drugs abandoned by sponsors during development.Possible risk factors for failure were analysed using statistically validated methods. This study points out that 437 out of 788 designations are still under development, while 219 failed the developmental process. Among the latter, 34 failed the marketing authorisation process and 185 were abandoned during the developmental process. In the first group of drugs (marketing authorisation failures), 50% reached phase II, 47% reached phase III and 3% reached phase I, while in the second group (abandoned drugs), the majority of orphan medicinal products apparently never started the development process, since no data on 48.1% of them were published and the 3.2% did not progress beyond the non-clinical stage.The reasons for failures of marketing authorisation were: efficacy/safety issues (26), insufficient data (12), quality issues (7), regulatory issues on trials (4) and commercial reasons (1). The main causes for abandoned drugs were efficacy/safety issues (reported in 54 cases), inactive companies (25.4%), change of company strategy (8.1%) and drug competition (10.8%). No information concerning reasons for failure was available for 23.2% of the analysed products. This analysis shows that failures occurred in 27.8% of all designations granted in Europe, the main reasons being safety and efficacy issues. Moreover, the stage of development reached by drugs represents a specific risk factor for failures.

Giannuzzi V ，Landi A ，Bosone E ，Giannuzzi F ，Nicotri S ，Torrent-Farnell J ，Bonifazi F ，Felisi M ，Bonifazi D ，Ceci A ... -  《BMJ Open》

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.

Giannuzzi V ，Conte R ，Landi A ，Ottomano SA ，Bonifazi D ，Baiardi P ，Bonifazi F ，Ceci A ... -  《Orphanet Journal of Rare Diseases》

[Hope for patients with rare diseases--"orphan" drugs].

Kuzelová M ，Kubácková K ，Palágyi M ，Smíd M ... -  《-》

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.

Pauwels K ，Huys I ，Casteels M ，Larsson K ，Voltz C ，Penttila K ，Morel T ，Simoens S ... -  《Orphanet Journal of Rare Diseases》

Drugs for rare diseases: mixed assessment in Europe.

《-》